skip to Main Content

Redx Pharma to Showcase Cancer Drug at Prestigious Munich Conference

Newsfeed image, light gray text on dark gray background
Drug developer Redx Pharma Plc is to present a pre-clinical profile of its exciting new Porcupine inhibitor at a cancer conference in Munich later today.

Drugs like Redx’s RXC004 work by targeting cancer stems cells that can often lie dormant after traditional treatment and are associated with a recurrence of the illness. Read more . . .

Back To Top